FDA approves Osphena for postmenopausal women with dyspareunia

Authosr(s):

On Feb. 26, 2013, the U.S. Food and Drug Administration (FDA) approved Osphena (ospemifene) to treat women with moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy caused by menopause. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here